LISINOPRIL TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

LISINOPRIL (LISINOPRIL DIHYDRATE)

Saatavilla:

COBALT PHARMACEUTICALS COMPANY

ATC-koodi:

C09AA03

INN (Kansainvälinen yleisnimi):

LISINOPRIL

Annos:

10MG

Lääkemuoto:

TABLET

Koostumus:

LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG

Antoreitti:

ORAL

Kpl paketissa:

30/100/500

Prescription tyyppi:

Prescription

Terapeuttinen alue:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0121550001; AHFS:

Valtuutuksen tilan:

CANCELLED PRE MARKET

Valtuutus päivämäärä:

2017-09-01

Valmisteyhteenveto

______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 1 of 44 _
_ _
_ _
PRODUCT MONOGRAPH
PR
LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
(of Lisinopril as Lisinopril Dihydrate)
Angiotensin Converting Enzyme Inhibitor
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
Canada, L5N 2B8
CONTROL NUMBER: 172480
Date of Revision:
March 4, 2014
______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 2 of 44 _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
.......................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........................